Lurati-Ruiz Floriana, Spertini François
Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
J Rheumatol. 2005 Nov;32(11):2167-72.
. The predictive value of antineutrophil cytoplasmic antibodies (ANCA) as markers of clinical activity of small vessel vasculitis is controversial. We reviewed the outcome of patients with ANCA-associated vasculitis from a single center and evaluated the predictive value of ANCA as markers of relapse.
The medical history of all consecutive patients with ANCA-associated vasculitis followed at our outpatient clinic was retrospectively reviewed. ANCA were monitored by immunofluorescence and by ELISA (antiproteinase 3 and antimyeloperoxidase).
Twenty-three patients with Wegener's granulomatosis and 13 with microscopic polyangiitis were followed for a median period of 5 years (1 mo-16 yrs). Most patients were treated with combined corticosteroids and cyclophosphamide. In the Wegener's granulomatosis group, remission was obtained in 21 of 23 patients (91%), within 4-48 weeks (median 7.5); relapses occurred in 74%. In the microscopic polyangiitis group, remission was obtained in all patients within 3-38 weeks (median 8); relapses occurred in 33%. In contrast to persistently (> 6 mo) elevated ANCA titers, which were not significantly associated with disease relapse, the predictive value of an acute rise in ANCA titers was strongly associated with the magnitude of the increase.
Our study demonstrates the weak predictive value of persistently elevated ANCA titers, in contrast to acute rises in ANCA titers. Although an acute rise in ANCA titers may help in a decision whether to introduce immunosuppressive therapy, the final decision has to be based on both clinical and laboratory markers.
抗中性粒细胞胞浆抗体(ANCA)作为小血管炎临床活动标志物的预测价值存在争议。我们回顾了来自单一中心的ANCA相关血管炎患者的预后情况,并评估了ANCA作为复发标志物的预测价值。
对在我们门诊随访的所有连续ANCA相关血管炎患者的病史进行回顾性分析。通过免疫荧光和酶联免疫吸附测定法(抗蛋白酶3和抗髓过氧化物酶)监测ANCA。
23例韦格纳肉芽肿患者和13例显微镜下多血管炎患者的中位随访时间为5年(1个月至16年)。大多数患者接受了糖皮质激素和环磷酰胺联合治疗。在韦格纳肉芽肿组中,23例患者中的21例(91%)在4至48周内(中位时间7.5周)获得缓解;74%的患者复发。在显微镜下多血管炎组中,所有患者在3至38周内(中位时间8周)获得缓解;33%的患者复发。与持续(>6个月)升高的ANCA滴度不同,持续升高的ANCA滴度与疾病复发无显著相关性,而ANCA滴度急性升高的预测价值与升高幅度密切相关。
我们的研究表明,与ANCA滴度急性升高相比,持续升高的ANCA滴度预测价值较弱。虽然ANCA滴度急性升高可能有助于决定是否引入免疫抑制治疗,但最终决定必须基于临床和实验室指标。